Robert Glanzman
Impact in
-
- Multiple Sclerosis Research Studies
- Neurology top 5%
- Peripheral Neuropathies and Disorders
- Botulinum Toxin and Related Neurological Disorders
- Amyotrophic Lateral Sclerosis Research
Papers in
-
- Multiple Sclerosis Research Studies 6
-
- Amyotrophic Lateral Sclerosis Research 3
- Co-authors
- Miroslav Bačkonja (1 shared paper)David Leppert (5 shared papers)Frederik Barkhof (3 shared papers)Ludwig Kappos (3 shared papers)David Li (1 shared paper)Peter A. Calabresi (2 shared papers)Paul O’Connor (1 shared paper)Ming Yin (1 shared paper)
- Journals
- Neurology (4 papers)The Lancet (2 papers)Multiple Sclerosis and Related Disorders (2 papers)Multiple Sclerosis Journal (2 papers)Annals of Neurology (1 paper)
- Partner nations
- United StatesSwitzerlandAustralia
In The Last Decade
Robert Glanzman
17 papers receiving 1.1k citations
Robert Glanzman's Hit Papers
Peers
Comparison fields: 5 of 89
- Pathology and Forensic Medicine 519
- Neurology 268
- Immunology 252
- Anesthesiology and Pain Medicine 46
- Physiology 204
Countries citing papers authored by Robert Glanzman
This map shows the geographic impact of Robert Glanzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Glanzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Glanzman more than expected).
Fields of papers citing papers by Robert Glanzman
This network shows the impact of papers produced by Robert Glanzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Glanzman. The network helps show where Robert Glanzman may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Glanzman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial Hit paper breakdown → | 2011 | 542 |
| 2 | 2003 | 302 | |
| 3 | 2007 | 76 | |
| 4 | 2021 | 64 | |
| 5 | 2021 | 34 | |
| 6 | 2023 | 34 | |
| 7 | 1990 | 29 | |
| 8 | 2023 | 28 | |
| 9 | 2021 | 27 | |
| 10 | 2012 | 16 | |
| 11 | 2016 | 13 | |
| 12 | 2017 | 4 | |
| 13 | 2023 | 2 | |
| 14 | 2012 | 2 | |
| 15 | 2012 | 1 | |
| 16 | 2012 | 1 | |
| 17 | 2012 | 1 |
About Robert Glanzman
Robert Glanzman is a scholar working on Pathology and Forensic Medicine, Neurology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Genetics, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (6 papers), Amyotrophic Lateral Sclerosis Research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Optical Coherence Tomography Applications (1 paper), Pain Management and Treatment (1 paper), Pharmaceutical industry and healthcare (1 paper), Neurogenetic and Muscular Disorders Research (1 paper) and Chromosomal and Genetic Variations (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (519 citations), Neurology (268 citations), Immunology (252 citations), Anesthesiology and Pain Medicine (46 citations) and Physiology (204 citations). Robert Glanzman has collaborated with scholars based in United States, Switzerland and Australia. Frequent co-authors include Miroslav Bačkonja, David Leppert, Frederik Barkhof, Ludwig Kappos, David Li, Peter A. Calabresi, Paul O’Connor, Ming Yin, Stephen L. Hauser and Amit Bar‐Or. Their work appears in journals such as Neurology, The Lancet, Multiple Sclerosis and Related Disorders, Multiple Sclerosis Journal and Annals of Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.